p53 and p21 Expression Levels Predict Organ Preservation and Survival in Invasive Bladder Carcinoma Treated with a Combined-Modality Approach

Cancer

Volumn 100, Issue 9, 2004, Pages 1859-1867

  Garcia Del Muro, Xavier ^a   Condom, Enric ^b   Vigués, Francesc ^b   Castellsagué, Xavier ^a   Figueras, Agnès ^a   Muñoz, Josep ^b   Solá, Judit ^a   Soler, Teresa ^b   Capellà, Gabriel ^a   Germà, Josep R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bladder carcinoma; Bladder preservation; p21; p53; pRB

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; METHOTREXATE; PLATINUM; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ORGAN PRESERVATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SAMPLING; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETER OBSTRUCTION;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 11144357075     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20200     Document Type: Article

References (35)

1. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993;329:1377-1382.
2. Vogelzang NJ, Moormeier JA, Awan AM, et al. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993;149:753-757.
3. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group Phase II trial 8802. J Clin Oncol. 1997;14:119-126.
4. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061-3071.
5. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259-1264.
6. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072-1079.
7. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRB expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998;58:1090-1094.
8. Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 1992;84:1256-1261.
9. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810.
10. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med. 1997;3:1034-1036.
11. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285-4300.
12. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr., O'Connor PM. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene. 1997;14:2127-2136.
13. waf expression in HI299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene. 1999;18:2643-2649.
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
15. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967.
16. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
17. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to chemotherapeutic agents. J Clin Invest. 1999;104:263-269.
18. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001;61:6185-6193.
19. Piovesan B, Pennell N, Berinstein NL. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene. 1998;17:2339-2350.
20. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994;54:3718-3722.
21. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 1995;13:1384-1390.
22. Qureshi KN, Griffiths TR, Robinson MC, et al. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res. 1999;5:3500-3507.
23. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature. 1997;385:123-125.
24. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independendent pathway. Cancer Res. 1994;54:3391-3395.
25. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996;10:1945-1952.
26. McDonald ER, Wu GS, Waldman T, EI-Deiry WS. Repair defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res. 1996;56:2250-2255.
27. Ruan S, Okcu MF, Pong RC, et al. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res. 1999;5:197-202.
28. Schmidt M, Fan Z. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors in CKI-responsive cells compared with CKI-unresponsive cells. Oncogene. 2001;20:6164-6171.
29. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 2000;60:679-684.
30. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311-320.
31. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996;381:713-716.
32. 1 arrest and induces apoptosis in human cancer cells. Oncogene. 1997;15:1903-1909.
33. Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol. 1999;161:20-23.
34. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res. 2000;6:1854-1864.
35. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059.